RecruitingPhase 2psilocybin
Psilocybin Therapy for Depression in Parkinson's Disease
Sponsored by Joshua Woolley, MD, PhD
NCT ID
NCT06455293
Target Enrollment
60 participants
Start Date
2024-08-19
Est. Completion
2028-06
About This Study
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
Conditions Studied
Interventions
- •Psilocybin
Eligibility
Age:40 Years - 80 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * Age 40 to 80 * Comfortable speaking and writing in English * Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect) * Currently experiencing depressive symptoms * Able to attend all in-person visits at UCSF as well as virtual visits * Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating Exclusion Criteria: * Psychotic symptoms involving loss of insight * Significant cognitive impairment * Regular use of medications that may have problematic interactions with psilocybin * A health condition that makes this study unsafe or unfeasible, determined by study physicians
Study Locations (1)
University of California, San Francisco
San Francisco, California, United States